Regulation of the wild-type and Y1235D mutant Met kinase activation.

Met receptor tyrosine kinase plays a crucial role in the regulation of a large number of cellular processes and, when deregulated by overexpression or mutations, leads to tumor growth and invasion. The Y1235D mutation identified in metastases was shown to induce constitutive activation and a motile-...

詳細記述

書誌詳細
主要な著者: Cristiani, C, Rusconi, L, Perego, R, Schiering, N, Kalisz, H, Knapp, S, Isacchi, A
フォーマット: Journal article
言語:English
出版事項: 2005
_version_ 1826303412162002944
author Cristiani, C
Rusconi, L
Perego, R
Schiering, N
Kalisz, H
Knapp, S
Isacchi, A
author_facet Cristiani, C
Rusconi, L
Perego, R
Schiering, N
Kalisz, H
Knapp, S
Isacchi, A
author_sort Cristiani, C
collection OXFORD
description Met receptor tyrosine kinase plays a crucial role in the regulation of a large number of cellular processes and, when deregulated by overexpression or mutations, leads to tumor growth and invasion. The Y1235D mutation identified in metastases was shown to induce constitutive activation and a motile-invasive phenotype on transduced carcinoma cells. Wild-type Met activation requires phosphorylation of both Y1234 and Y1235 in the activation loop. We mapped the major phosphorylation sites in the kinase domain of a recombinant Met protein and identified the known residues Y1234 and Y1235 as well as a new phosphorylation site at Y1194 in the hinge region. Combining activating and silencing mutations at these sites, we characterized in depth the mechanism of activation of wild-type and mutant Met proteins. We found that the phosphotyrosine mimetic mutation Y1235D is sufficient to confer constitutive kinase activity, which is not influenced by phosphorylation at Y1234. However, the specific activity of this mutant was lower than that observed for fully activated wild-type Met and induced less phosphorylation of Y1349 in the signaling site, indicating that this mutation cannot entirely compensate for a phosphorylated tyrosine at this position. The Y1194F silencing mutation yielded an enzyme that could be activated to a similar extent as the wild type but with significantly slower activation kinetics, underlying the importance of this residue, which is conserved among different tyrosine kinase receptors. Finally, we observed different interactions of wild-type and mutant Met with the inhibitor K252a that may have therapeutic implications for the selective inhibition of this kinase.
first_indexed 2024-03-07T06:02:17Z
format Journal article
id oxford-uuid:ec9f9df0-a045-4e50-a3e7-3d10f5702812
institution University of Oxford
language English
last_indexed 2024-03-07T06:02:17Z
publishDate 2005
record_format dspace
spelling oxford-uuid:ec9f9df0-a045-4e50-a3e7-3d10f57028122022-03-27T11:18:50ZRegulation of the wild-type and Y1235D mutant Met kinase activation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ec9f9df0-a045-4e50-a3e7-3d10f5702812EnglishSymplectic Elements at Oxford2005Cristiani, CRusconi, LPerego, RSchiering, NKalisz, HKnapp, SIsacchi, AMet receptor tyrosine kinase plays a crucial role in the regulation of a large number of cellular processes and, when deregulated by overexpression or mutations, leads to tumor growth and invasion. The Y1235D mutation identified in metastases was shown to induce constitutive activation and a motile-invasive phenotype on transduced carcinoma cells. Wild-type Met activation requires phosphorylation of both Y1234 and Y1235 in the activation loop. We mapped the major phosphorylation sites in the kinase domain of a recombinant Met protein and identified the known residues Y1234 and Y1235 as well as a new phosphorylation site at Y1194 in the hinge region. Combining activating and silencing mutations at these sites, we characterized in depth the mechanism of activation of wild-type and mutant Met proteins. We found that the phosphotyrosine mimetic mutation Y1235D is sufficient to confer constitutive kinase activity, which is not influenced by phosphorylation at Y1234. However, the specific activity of this mutant was lower than that observed for fully activated wild-type Met and induced less phosphorylation of Y1349 in the signaling site, indicating that this mutation cannot entirely compensate for a phosphorylated tyrosine at this position. The Y1194F silencing mutation yielded an enzyme that could be activated to a similar extent as the wild type but with significantly slower activation kinetics, underlying the importance of this residue, which is conserved among different tyrosine kinase receptors. Finally, we observed different interactions of wild-type and mutant Met with the inhibitor K252a that may have therapeutic implications for the selective inhibition of this kinase.
spellingShingle Cristiani, C
Rusconi, L
Perego, R
Schiering, N
Kalisz, H
Knapp, S
Isacchi, A
Regulation of the wild-type and Y1235D mutant Met kinase activation.
title Regulation of the wild-type and Y1235D mutant Met kinase activation.
title_full Regulation of the wild-type and Y1235D mutant Met kinase activation.
title_fullStr Regulation of the wild-type and Y1235D mutant Met kinase activation.
title_full_unstemmed Regulation of the wild-type and Y1235D mutant Met kinase activation.
title_short Regulation of the wild-type and Y1235D mutant Met kinase activation.
title_sort regulation of the wild type and y1235d mutant met kinase activation
work_keys_str_mv AT cristianic regulationofthewildtypeandy1235dmutantmetkinaseactivation
AT rusconil regulationofthewildtypeandy1235dmutantmetkinaseactivation
AT peregor regulationofthewildtypeandy1235dmutantmetkinaseactivation
AT schieringn regulationofthewildtypeandy1235dmutantmetkinaseactivation
AT kaliszh regulationofthewildtypeandy1235dmutantmetkinaseactivation
AT knapps regulationofthewildtypeandy1235dmutantmetkinaseactivation
AT isacchia regulationofthewildtypeandy1235dmutantmetkinaseactivation